Healthcare -
Biotechnology - NASDAQ - US
$ 13.88
-5 %
$ 90.6 M
Market Cap
-1.22
P/E
1. INTRINSIC VALUE
Balance Sheet
Instil Bio, Inc.
| Current Assets | 124 M |
| Cash & Short-Term Investments | 113 M |
| Receivables | 0 |
| Other Current Assets | 11.2 M |
| Non-Current Assets | 139 M |
| Long-Term Investments | 0 |
| PP&E | 130 M |
| Other Non-Current Assets | 8.76 M |
| Current Liabilities | 7.9 M |
| Accounts Payable | 659 K |
| Short-Term Debt | 0 |
| Other Current Liabilities | 7.24 M |
| Non-Current Liabilities | 86.2 M |
| Long-Term Debt | 2.03 M |
| Other Non-Current Liabilities | 84.2 M |
EFFICIENCY
Earnings Waterfall
Instil Bio, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 73.5 M |
| Operating Income | -73.5 M |
| Other Expenses | 594 K |
| Net Income | -74.1 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Instil Bio, Inc.
| Net Income | -74.1 M |
| Depreciation & Amortization | 3.61 M |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 17.3 M |
| Change in Working Capital | -12.6 M |
| Others | -1.87 M |
| Free Cash Flow | -55.7 M |
Wall Street Analysts Price Targets
Instil Bio, Inc.
Wall Street analysts predict an average 1-year price target for TIL of $113 , with forecasts ranging from
a
low of
$40 to a high of $180 .
TIL Lowest Price Target
Wall Street Target
40 USD
188.18%
TIL Average Price Target
Wall Street Target
113 USD
716.52%
TIL Highest Price Target
Wall Street Target
180 USD
1196.83%
4. DIVIDEND
ANALYSIS
TIL does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Instil Bio, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Clinical data for AXN-2510/IMM2510 monotherapy in relapsed/refractory NSCLC in China by ImmuneOnco, as well as additional safety data in other solid tumors, anticipated in 1H 2025
globenewswire.com
- 1 month ago
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China
globenewswire.com
- 3 months ago
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
Jefferies upgraded Instil Bio TIL, noting that 2024 was a banner year for the PD-(L)1xVEGF class.
benzinga.com
- 3 months ago
Instil Bio's Strategic Shift To SYN-2510: A Speculative 'Buy' Opportunity
Instil Bio is a clinical-stage biotech focusing on personalized immunotherapy. SYN-2510 targets the promising PD-L1/VEGF oncology pathway. The company recently licensed assets from ImmuneOnco Biopharmaceuticals, retaining commercialization rights outside Greater China and enhancing its global market positioning. SYN-2510 is advancing to Phase 2 trials for NSCLC and TNBC, addressing a TAM forecasted to reach $43.7 billion by 2026.
seekingalpha.com
- 4 months ago
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Turnstone's next-generation Selected TIL technology is designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors Results further support the continued clinical advancement of TIDAL-01, currently being evaluated in Phase 1 trials SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced it will be presenting two posters highlighting preclinical data on methods for TIL selection at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6-10, 2024 in Houston, Texas. “We remain confident that delivering a TIL-based product with a higher proportion of tumor-reactive T cells is the key to extending the clinical application of TILs across a broader range of solid tumors,” said David Stojdl, Ph.D.
globenewswire.com
- 5 months ago
2 Stocks Up Over 700% in 2024 That Could Soar Even Further
Summit Therapeutics' stock is way up in response to clinical trial results that suggest the cancer therapy it's developing could become the standard of care for lots of patients. Instil Bio stock soared because it's developing a bispecific antibody similar to the candidate that pushed up Summit Therapeutics.
fool.com
- 6 months ago
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 1% on Monday.
benzinga.com
- 7 months ago
Instil Bio Stock Skyrockets 641% in One Week: Here's Why
A rival posted encouraging data on a drug that outperformed Keytruda in certain NSCLC patients. TIL licenses a drug candidate that uses a similar mechanism.
zacks.com
- 7 months ago
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
DALLAS and SHANGHAI, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX:1541, “ImmuneOnco”) announced today the global registrational strategy for the PD-L1xVEGF bispecific antibody SYN-2510/IMM2510 in combination with chemotherapy in front-line non-small cell lung cancer (NSCLC) and in front-line triple-negative breast cancer (TNBC).
globenewswire.com
- 7 months ago
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?
Instil Bio is developing a bispecific antibody that strengthens immune responses to solid tumors by simultaneously targeting PD-L1 and VEGF. Instil Bio's lead immunology candidate is still in phase 1 testing, but a similar candidate from Summit Therapeutics recently outperformed Keytruda.
fool.com
- 7 months ago
Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements
Instil Bio, Inc. in-licensing brings on board high demand IMM2510 clinical product with PD-L1/VEGF targeting of solid tumors; proof-of-concept established by Summit/Akeso and BioNTech. Two competitive advantages of IMM2510 would be the ability to bind to other VEGF ligands beyond that of VEGF-A only and to have enhanced ADCC killing. In-licensing deal with ImmuneOnco also brings on board next-generation anti-CTLA-4 antibody IMM27M, which also has enhanced ADCC killing.
seekingalpha.com
- 7 months ago
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its second quarter 2024 financial results and provided a corporate update.
globenewswire.com
- 8 months ago
8. Profile
Summary
Instil Bio, Inc. TIL
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 90.6 M
Dividend Yield
0.00%
Description
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
Contact
3963 Maple Avenue, Dallas, TX, 75219
https://instilbio.com
IPO
Date
March 19, 2021
Employees
14
Officers
Dr. Sandeep Laumas M.D.
Chief Financial Officer & Chief Business Officer
Mr. Bronson Crouch
Chairman & Chief Executive Officer
Dr. Andres A. Gutierrez M.D., Ph.D.
Chief Medical Officer